Table of Contents 3
List of Tables 4
List of Figures 4
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Denovo Biopharma LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Denovo Biopharma LLC, Medical Devices Deals, 2012 to YTD 2018 9
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Denovo Biopharma Acquires Global Rights to Enzastaurin from Eli Lilly 11
Venture Financing 12
Denovo Biopharma Raises Funds in Series A Financing Round 12
Partnerships 13
ALS Emergency Treatment Fund And Denovo Biomarkers Partner To Explore Personalized Medicine Approach For ALS Treatments 13
Licensing Agreements 14
Denovo Biopharma Enters into Licensing Agreement with Stanford University 14
Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 15
Denovo Biopharma Enters into Licensing Agreement with Eli Lilly for Pomaglumetad Methionil 16
Denovo Biopharma LLC - Key Competitors 17
Denovo Biopharma LLC - Key Employees 18
Denovo Biopharma LLC - Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Clinical Trials 20
Apr 03, 2018: First Patient Dosed In Pivotal Biomarker-Guided Phase 3 Study Of First Line Therapy With DB102 (enzastaurin) + R-CHOP In Patients With High-Risk Diffuse Large B-Cell Lymphoma 20
Oct 24, 2017: Denovo Biopharma Receives FDAs Permission to Proceed a Phase 3 Clinical Trial with DB102 (Enzastaurin) in the First Line Treatment of High Risk DLBCL 21
Feb 16, 2017: Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Key Facts 2
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Denovo Biopharma LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Denovo Biopharma LLC, Deals By Therapy Area, 2012 to YTD 2018 8
Denovo Biopharma LLC, Medical Devices Deals, 2012 to YTD 2018 9
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denovo Biopharma Acquires Global Rights to Enzastaurin from Eli Lilly 11
Denovo Biopharma Raises Funds in Series A Financing Round 12
ALS Emergency Treatment Fund And Denovo Biomarkers Partner To Explore Personalized Medicine Approach For ALS Treatments 13
Denovo Biopharma Enters into Licensing Agreement with Stanford University 14
Denovo Biopharma Enters into Licensing Agreement with Albany Molecular Research 15
Denovo Biopharma Enters into Licensing Agreement with Eli Lilly for Pomaglumetad Methionil 16
Denovo Biopharma LLC, Key Competitors 17
Denovo Biopharma LLC, Key Employees 18

List of Figures
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Denovo Biopharma LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Denovo Biopharma LLC, Medical Devices Deals, 2012 to YTD 2018 9